Milestone Pharma has officially established its first overseas site, Milestone Pharma Singapore Pte. Ltd., marking an important step in the development of the company’s global service network. The Singapore subsidiary has completed registration, and its advanced analytical technology laboratory is now in active preparation at Singapore Science Park.
The Singapore site will serve as a key analytical service node for Milestone Pharma in Asia-Pacific, providing localized, compliant, and highly efficient analytical testing, pharmaceutical quality research, and regulatory support services for global pharmaceutical and biotechnology companies.
Based in Singapore, Connected to Asia-Pacific and Global Markets
Singapore is an important biomedical R&D and commercialization hub in Asia-Pacific, bringing together global pharmaceutical companies, innovative biotechnology companies, research institutions, and professional service resources. As a key node connecting Southeast Asia, Japan, South Korea, Australia, and global markets, Singapore provides an efficient industry environment for cross-regional drug development, regulatory submissions, and supply chain management.
As a PIC/S member country, Singapore has an internationally aligned GMP regulatory environment. Leveraging this advantage, Milestone Pharma Singapore will provide analytical support that is closer to regional regulatory requirements for clients’ R&D, pharmaceutical quality research, and multi-country regulatory submissions across Asia-Pacific and global markets.
Three Core Needs, One Integrated Analytical Solution
Milestone Pharma Singapore will provide localized and compliant one-stop analytical solutions addressing the analytical characterization needs of global pharmaceutical and biotechnology companies in cross-regional R&D, global supply chain management, and multi-country regulatory submissions.
1.Supporting Global Supply Chain Analytical Needs
As pharmaceutical companies continue to expand their R&D, manufacturing, and supply chain footprints into Asia-Pacific and broader international markets, analytical testing services also need to be closer to regional markets and regulatory environments. Milestone Pharma Singapore can serve as an Asia-Pacific analytical node, conducting testing under the PIC/S GMP framework, with relevant data applicable to multi-country regulatory submissions.
In response to practical challenges such as sample stability risks during cross-border transportation, method reproducibility requirements under different regulatory systems, and response efficiency for cross-regional projects, the Singapore laboratory will provide systematic analytical support to help clients improve the efficiency of global supply chain quality management.
2. Supporting Asia-Pacific and Global Regulatory Submissions and Data Recognition
For submissions to Asia-Pacific regulatory authorities such as Singapore’s HSA, Malaysia’s NPRA, and Indonesia’s BPOM, as well as other international regulatory submission needs, Milestone Pharma Singapore can complete analytical testing locally in Singapore, reducing the need for cross-border sample shipment and improving project response efficiency. Based on the current plan, the regional service model is expected to shorten cross-border service response cycles by approximately 50%.
Analytical reports issued under the PIC/S framework can support multi-country regulatory submissions and complement data generated under regulatory systems such as China’s NMPA, the U.S. FDA, and the EU EMA, helping companies build more efficient and flexible global submission strategies.
3. Enabling Global Advanced Drug Development with Cutting-Edge Analytical Technologies
For frontier therapeutic areas such as biologics, nanomedicines, advanced therapy medicinal products, peptides, oligonucleotides, and advanced delivery systems, the identification, characterization, and control of complex quality attributes have become critical in global R&D, registration, and manufacturing processes.
Milestone Pharma has accumulated systematic technical capabilities in advanced structural characterization, complex formulation analysis, sequence confirmation, impurity studies, and analytical method development and validation. After the Singapore laboratory is completed, these advanced analytical platforms will be introduced to the Asia-Pacific market, providing high-level analytical characterization support for global pharmaceutical and biotechnology companies during R&D, registration, and manufacturing stages.
China–Singapore Dual-Center Collaboration for Global Project Delivery
Milestone Pharma will build a China–Singapore dual-center collaborative service model. Analytical work that can be completed in China will continue to be supported by the China team, while projects requiring PIC/S system recognition or Asia-Pacific regional delivery can be supported by the Singapore laboratory.
Under a unified quality system, the dual-center model will connect Milestone Pharma’s technical platforms in China with Singapore’s regional service capabilities, improve cross-regional project delivery efficiency, and enable clients to flexibly allocate analytical resources under different regulatory pathways.
Through this model, Milestone Pharma will further strengthen its capabilities in pharmaceutical quality research, analytical characterization, regulatory submissions, and commercialization support across Asia-Pacific and global markets.
Open Collaboration Across the Global Pharmaceutical Innovation Ecosystem
Global pharmaceutical innovation depends on collaboration across all parts of the value chain. Milestone Pharma Singapore Pte. Ltd. has completed registration, and its laboratory is now in active preparation at Singapore Science Park. Milestone Pharma looks forward to connecting with a wide range of partners across the global pharmaceutical and biotechnology ecosystem.
We welcome collaboration with:
Pharmaceutical and biotechnology companies advancing Asia-Pacific or global regulatory submissions;
Companies seeking compliant analytical support for R&D, pharmaceutical quality research, and manufacturing;
Industry partners with an established presence in Southeast Asia or the broader Asia-Pacific region;
Instrument and equipment manufacturers seeking technical cooperation in regional markets.
Whether you have project needs, collaboration ideas, or technical resources, Milestone Pharma welcomes the opportunity to connect and explore new possibilities together.
Looking Ahead
The establishment of Milestone Pharma Singapore is an important step in the company’s global expansion. By strengthening its regional node in Singapore, Milestone Pharma will build a more agile analytical service platform that is closer to Asia-Pacific markets while continuously enhancing its global regulatory support capabilities.
Looking ahead, Milestone Pharma will rely on its China–Singapore dual-center collaborative service network to continuously enhance its capabilities in analytical characterization, pharmaceutical quality research, and regulatory compliance support, providing high-quality technical support for innovative medicines from R&D to registration and from regional markets to global commercialization.
